Novo Nordisk Foundation awarded more than DKK 9.1 billion for purposes benefitting society in 2023
Focusing its support on science, education, innovation and development…
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:…
Women in Life Science Denmark (WiLD) to host network meeting in collaboration with DANISH BIO to promote equity in the Danish life science industry
Keynote speaker Margrethe Vestager, EU commissioner and EVP of…
Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases
Significant appointments of industry and academic experts…
Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
Ladenburg, Germany, 6 March 2024 – Heidelberg Pharma AG (FSE:…
Novo Holdings Venture Investments 2023 Newsletter: A record year advancing innovative therapies for patients
18 new portfolio investments
Five portfolio companies…
Fibrocor Therapeutics enters into research and development collaboration with McQuade Center for Strategic Research and Development to advance Alport Syndrome program
Agreement includes a single digit million US$ upfront payment…
Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials
First patent application registered
BRAIN Biotech relies…
Ariceum Therapeutics announces opening of new state-of-the-art laboratory in Berlin providing infrastructure for radiopharmaceutical development activities
Berlin, Germany, 5 March 2024 – Ariceum Therapeutics (Ariceum),…
Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
HealthCare Royalty to purchase royalties from worldwide sales…
4SC Files Marketing Authorisation Application with EMA for Resminostat (Kinselby)
Planegg-Martinsried, Germany, 1 March 2024 – 4SC AG (4SC,…
Ariceum Therapeutics Granted UK Authorisation to Conduct Phase I Clinical Study of its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblastoma
Berlin, Germany, 29th February 2024 – Ariceum Therapeutics…
Rare Disease Day 2024 – Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy
Barcelona, Spain and Düsseldorf, Germany – 29 February, 2024 –…
Bionical Solutions Appoints Chief Technology Officer to Create Innovative Data Products and Software for the Digital Business
WILLINGTON, England, Feb. 29, 2024 - Bionical Solutions, a…
BII welcomes twelve new companies to its Venture Lab program
BioInnovation Institute (BII), an international non-profit foundation…
Curve Therapeutics raises £40.5 million to turbocharge discovery platform and advance breakthrough pipeline
Series A financing led by Pfizer Ventures with new investors…
Neuraxpharm announces the first launch of BRIUMVI® (ublituximab) in Europe for the treatment of relapsing multiple sclerosis
Germany is the first European country to launch ublituximab,…
Kling Biotherapeutics to Present Discoveries on its Primary B-Cell Screening Platform at the ESMO Targeted Anticancer Therapies Congress
Kling reports on advancing pipeline of therapeutic antibodies…
STORM Therapeutics to Present Findings on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at ESMO Targeted Anticancer Therapies Congress
Data demonstrates pharmacological inhibition of METTL1 inhibits…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York